ASCRSMedia Media Kit

Media Kit 2013

ASCRSMedia offers print and online advertising opportunities for ASCRS, ASOA, and EyeWorld, as well as a variety of marketing and advertising opportunities during the annual ASCRS Symposium and Congress, APACRS, and other global meetings.

Issue link:

Contents of this Issue


Page 23 of 75

Reprints Use your appearance in EyeWorld to gain benefits in addition to your presence in the issue in which it initially appears. An EyeWorld reprint is custom designed and reproduced as a presentation-grade item suitable for distribution to your sales people and clients. All reprints are quoted individually based on the number of pages required and the quantity to be printed. Contact our production department to obtain a quote for reprints from EyeWorld, the ASCRS member's most trusted source for products and services. To obtain a quote, contact: Cathy Stern Production Manager ASCRSMedia Production Department Phone: 703-383-5702 Email: Fax: 703-547-8831 AS SEEN IN REPRINTED FROM THE MONDAY EYEWORLD SAN DIEGO SUPPLEMENT 2011 The News Magazine of the American Society of Cataract and Refractive Surgery Capitalize on advanced technology for today's surgeon Better biomechanics for all-laser LASIK vs. traditional LASIK FS200 femtosecond preserves patient eye health, surgeon says F emtosecond lasers have been making LASIK flaps for at least a decade. Up until now, practitioners have heard a lot about femtosecond lasers in ophthalmology, but not nearly as much about the WaveLight FS200 Femtosecond Laser (Alcon, Fort Worth, Texas). Does it deliver in terms of flap- making performance? How will it sup- port eye health in eyes that undergo the LASIK procedure? What sets it apart from the competition? Ronald Krueger, M.D., medical director, department of refractive surgery, Cole Eye Institute, and profes- sor of ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, is an excited user of the FS200 technology. "It's a newer femtosecond laser that has a fast pulse repetition rate of 200 kHz," Dr. Krueger said. Such speed pro- vides standard flap creation in about 6 seconds, according to Alcon. Dr. Krueger said that the impact of this laser on the biomechanical proper- ties of the cornea is considerably improved compared to other femtosec- ond lasers in the marketplace. For one, he is eager to use the system more because of its advanced suction mecha- nism that reduces IOP increases during LASIK. "It has two suctions instead of one," Dr. Krueger said. "The first one is able to give an adequate fixation on the eye. The second one is to applanate the cornea, and it sucks into the ring already fixated on the eye." The geometry of the ring is such that it has a special spacer (distance pieces), which deforms the sclera less than a standard suction ring with the IntraLase (Abbott Medical Optics, Santa Ana, Calif.), Dr. Krueger said. The result is that IOP doesn't have to rise as high with the FS200, improving patient safe- ty. "The IOP rise with the FS200, in my opinion, is lower compared to the IntraLase," Dr. Krueger said. "Surgeons would like to avoid excessive IOP rise. We don't want to have too much stress on the eye. Patients can have glauco- ma, in which case you can do LASIK but you don't want to have too much stress." Consistent suction is applied via automated vacuum control of the patient interface, while ocular distor- tion is minimized, according to Alcon. Bubbles created by the femtosec- ond pulses are released in a less con- cerning manner with the FS200 laser. With the IntraLase, Dr. Krueger said, laser pulses can yield bubbles that become sequestered in the cornea. Instead of being released, the bubbles can form an opaque bubble layer (OBL), he said. With the FS200, there is a ventila- tion path that allows the bubbles to escape more efficiently. This is designed to minimize the formation of OBL by Ronald Krueger, M.D. "The FS200 is faster, has two suction pumps for less manipulation getting things lined up with the interface, affords less IOP rise, yields better flap predictability because of the beam control check, and results in less OBL PUBLICATIONS " Copyright 2011, ASCRS Ophthalmic Services Corp. All rights reserved. AS SEEN IN REPRINTED FROM MARCH 2011 The News Magazine of the American Society of Cataract and Refractive Surgery With the treatment closer to FDA approval in the U.S., EyeWorldlooks at the details of corneal crosslinking in practice Anxiously awaiting corneal crosslinking by Enette Ngoei EyeWorld Contributing Editor C orneal collagen crosslinking (CCL) has been utilized for the treatment of corneal ectasia throughout the world. Studies have demonstrated the benefits of this technique as a treatment to stabilize corneas that are demonstrating progressive ectasia. CCL has been used in patients with keratoconus to prevent further thinning and steeping of the cornea, thus preventing the need for a keratoplasty. In addition, CCL has been utilized as the first-line therapy for patients with post-corneal refractive ectasia to prevent further corneal changes and in some cases achieve a slight reversal of the corneal steepening. The largest potential clinical application of CCL may be in pro- phylaxis rather than treatment of ectasia. Some clinicians are advo- cating the use of this treatment for all patients who are diagnosed with keratoconus or pellucid marginal degeneration before the cornea has developed significant steepening and irregular astigmatism. Another prophy- laxis possibility is the corneal refractive patient at a higher risk for ectasia with the CCL treatment given pre-operatively or intraopera- tively. Finally, the use of CCL is being explored in patients with established keratoconus to allow for the possibility of subsequent corneal refractive surgery. Unfortunately, CCL does not have FDA approval in the U.S. at this time. Therefore U.S. patients are not receiving what appears to be a safe and effective in-office procedure that in many cases will prevent the progression of ectasia and the need for a keratoplasty. I have asked Drs. Donnenfeld and Stulting, U.S. refractive surgeons who have been active in CCL research, to give their views. In addition, Dr. Stein, a very experienced CCL clinician in Canada, shares his insights. Edward J. Holland, M.D., cornea editor C orneal collagen crosslinking as the standard of care treatment for progressive keratoconus and post- LASIK ectasia has been available in Canada for more than 4 years and in Europe for even longer. In the U.S., there are several clinical trials being conduct- ed, and the one that's closest to resolution is one sponsored by Avedro Inc. (Waltham, Mass.), said Eric D. Donnenfeld, M.D., co-chairman, Cornea, Nassau University Medical Center, East Meadow, N.Y. "That data has been submitted to the FDA, and we're look- ing forward to seeing that approved," he said. An effective treatment Keratoconus is the second most common cause of corneal transplants in the United States, and with crosslinking, it can virtually be eliminated, Dr. Donnenfeld said. The document of literature shows that corneal crosslinking overwhelmingly stops the progression of keratoconus or ectasia and that there's a mean of approximately 1.0-2.0 D of flatten- ing of the cornea as well, he said. While the data on post-LASIK ectasia patients is not quite as good as with keratoconic patients, it's still good, Dr. Donnenfeld said. R. Doyle Stulting, M.D., Woolfson Eye Institute, Atlanta, who is involved with clinical trials sponsored by Topcon Medical Systems (Oakland, N.J.), also said the treatment is very effective, based on international data. Raymond Stein, M.D., medical director, Bochner Eye Institute, Toronto, whose practice was the first in Canada to become involved with corneal crosslinking, said, "We've been doing it for 4-and-a-half years, and we've treated approximately 2,500 eyes in that period. We haven't seen any patient who's shown progression, and we've treated patients as young as 10 years of age." The majority of his patients are between 18 and 30, but he has also treated patients whose ages range from 10 all the way up to 60. "It's an extremely effective procedure at preventing pro- gression," Dr. Stein said. PUBLICATIONS Copyright 2011, ASCRS Ophthalmic Services Corp. All rights reserved.

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCRSMedia Media Kit - Media Kit 2013